KVUE Price Prediction Next Week
Technical Analysis
Recent price action shows KVUE trading in a consolidation pattern between $18.47-$18.94. The stock has formed a series of higher lows, suggesting building momentum.
News Sentiment & Event Impact
- Recent takeover speculation has driven a 2% gain, with potential interest from P&G or Unilever
- Activist investor Starboard Value's proxy battle and push for improvements in skin, health, and beauty segments adds positive catalyst potential
- RBC Capital maintains Hold rating with $24 price target
Price Projection (Next Trading Week) Based on technical indicators and news catalysts:
Target Ranges:
- Support: $18.45
- Resistance: $19.20
- Most Likely Range: $18.70-$19.10
Trading Recommendation BUY with entry at current levels ($18.79-18.80)
- Set stop loss at $18.40
- First target: $19.10 (+1.6%)
- Second target: $19.20 (+2.1%)
Rationale:
- Positive momentum from takeover speculation
- Activist involvement creating value catalyst
- Technical support at $18.45-18.50 zone
- Risk/reward ratio favorable for long positions
KVUE Similar Chart Price Prediction
The price of KVUE is predicted to go up -20.41%, based on the high correlation periods with BLZE. The similarity of these two price pattern on the periods is 94.26%.
KVUE
BLZE
Down: -20.41%Similarity: 94.26%
KVUE Revenue Forecast
KVUE EPS Forecast
KVUE FAQs
What is bull’s view on KVUE?
What is bear's view on KVUE?
What is KVUE revenue forecast for next quarter？
What is KVUE eps forecast for next quarter？
KVUE VS S&P500
With autonomy from its former parent, Kenvue can allocate resources to best fit its needs and grow the business.
Macro drivers like an aging population and premiumization of health care will act as tailwinds for all of Kenvue's brands.
Kenvue's continued focus on digital advertising and marketing will keep the company well-positioned to fend off any new competitors in e-commerce.
KVUE Analyst's Forecast
Korinne Wolfmeyer
Piper Sandler
Buy
2025-02-24
Price Target
$24 → $27
Upside
+15.88%
Piper Sandler raised the firm's price target on Kenvue to $27 from $24 and keeps an Overweight rating on the shares. The firm notes guidance was reiterated, which continues to include some disruption in the first half of the year. However, confidence around the second half remains, and updates around progress in Skin Health & Beauty is creating some more optimism. The team also seems to have a stronger sense of urgency to drive more improvement, which if executed on properly, could create a compelling setup for investors with shares still at a discount, Piper adds.
Lauren Lieberman
Barclays
Hold
2025-01-17
Price Target
$23 → $21
Downside
-0.47%
Filippo Falorni
Citigroup
Hold
2025-01-15
Price Target
$25 → $21
Upside
+0.72%
